Hidradenitis Suppurativa and Bipolar Disorders: A Population-Based Study

Dermatology ◽  
2020 ◽  
Vol 236 (4) ◽  
pp. 298-304 ◽  
Author(s):  
Dana Tzur Bitan ◽  
Daniella Berzin ◽  
Arnon Cohen

Background: Psychological comorbidities have been reported in patients with hidradenitis suppurativa (HS), yet only a few studies have investigated the possible association between HS and severe psychiatric disorders. The current study aimed to assess the association between HS and bipolar disorder, a major, chronic, psychiatric disease. Methods: A nationwide, population-based study was performed utilizing data from the Clalit Health Services (CHS) database in Israel. The study included 4,191 HS patients and 20,941 age- and gender-matched controls. A multivariate binary logistic regression, adjusted for demographic and behavioral risk factors, was performed. Results: A higher proportion of bipolar disorders was found among HS patients compared to controls (0.7 vs. 0.1%, respectively). There was an increased proportion of active smokers among HS patients than among controls (53.4 vs. 13.5%, respectively). In the multivariate analysis, adjusting for age, sex, and smoking, HS was found to be independently and positively associated with bipolar disorders (OR 2.12, 95% CI 1.21–3.27, p < 0.01), yet after controlling for body mass this association became nonsignificant. Conclusions: Bipolar disorders are associated with HS. Future studies should explore whether cardiometabolic deficiencies might account for this association. Healthcare providers should consider this potential co-occurrence as it may impede patient compliance and require appropriate screening and treatment. Results also stress the need for a multidisciplinary approach to optimize management of the disease and its associated comorbidities.

Author(s):  
Yun‐Tzu Liang ◽  
Chih‐Jung Yeh ◽  
Jing‐Yang Huang ◽  
James Cheng‐Chung Wei

2013 ◽  
Vol 133 (1) ◽  
pp. 97-103 ◽  
Author(s):  
Benjamin G. Vazquez ◽  
Ali Alikhan ◽  
Amy L. Weaver ◽  
David A. Wetter ◽  
Mark D. Davis

Author(s):  
Jasmin Honkamäki ◽  
Päivi Piirilä ◽  
Hanna Hisinger-Mölkänen ◽  
Leena E. Tuomisto ◽  
Heidi Andersen ◽  
...  

2021 ◽  
pp. 089826432110464
Author(s):  
Karen I. Fredriksen-Goldsen ◽  
Hailey Jung ◽  
Hyun-Jun Kim ◽  
Ryan Petros ◽  
Charles Emlet

Objectives: This is the first national population-based study to examine cognitive impairment disparities among sexual minority mid-life and older adults. Methods: Using the National Health Interview Survey (2013–2018), we compared weighted prevalence of subjective cognitive impairment by sexual orientation and gender, among those aged 45 plus, applying logistic regressions adjusting for age, income, education, race/ethnicity, and survey years. Results: Sexual minorities (24.5%) were more likely to have subjective cognitive impairment than heterosexuals (19.1%). Sexual minority women had higher odds of greater severity, frequency, and extent of subjective cognitive impairment. Sexual minorities were also more likely to report activity limitations resulting from cognitive impairment and were no more likely to attribute limitations to dementia or senility. Discussion: Cognitive health disparities are of particular concern in this historically and socially marginalized population. The investigation of explanatory factors is needed, and targeted interventions and policies are warranted to address cognitive challenges faced by sexual minorities.


2020 ◽  
Vol 83 (6) ◽  
pp. AB218
Author(s):  
Maria Schneeweiss ◽  
Sebastian Schneeweiss ◽  
Richard Wyss ◽  
Joseph Merola ◽  
David Rosmarin

BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e033944
Author(s):  
Oskar Bergengren ◽  
Hans Garmo ◽  
Ola Bratt ◽  
Lars Holmberg ◽  
Eva Johansson ◽  
...  

ObjectiveKnowledge about factors influencing choice of and adherence to active surveillance (AS) for prostate cancer (PC) is scarce. We aim to identify which factors most affected choosing and adhering to AS and to quantify their relative importance.Design, setting and participantsIn 2015, we sent a questionnaire to all Swedish men aged ≤70 years registered in the National Prostate Cancer Register of Sweden who were diagnosed in 2008 with low-risk PC and had undergone prostatectomy, radiotherapy or started on AS.Outcome measurements and statistical analysisLogistic regression was used to calculate ORs with 95% CIs for factors potentially affecting choice and adherence to AS.Results1288 out of 1720 men (75%) responded, 451 (35%) chose AS and 837 (65%) underwent curative treatment. Of those starting on AS, 238 (53%) diverted to treatment within 7 years. Most men (83%) choose AS because ‘My doctor recommended AS’. Factors associated with choosing AS over treatment were older age (OR 1.81, 95% CI 1.29 to 2.54), a Charlson Comorbidity Index >2 (OR 1.50, 95% CI 1.06 to 2.13), being unaccompanied when notified of the cancer diagnosis (OR 1.45, 95% CI 1.11 to 1.89). Men with a higher prostate-specific antigen (PSA) at the time of diagnosis were less likely to adhere to AS (OR 0.26, 95% CI 0.10 to 0.63). The reason for having treatment after initial AS was ‘the PSA level was rising’ in 55% and biopsy findings in 36%.ConclusionsA doctor’s recommendation strongly affects which treatment is chosen for men with low-risk PC. Rising PSA values were the main factor for initiating treatment for men on AS. These findings need be considered by healthcare providers who wish to increase the uptake of and adherence to AS.


Sign in / Sign up

Export Citation Format

Share Document